Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Supportive care and symptom management (EONS-MASCC)

CN48 - A qualitative study of patient and clinician experiences of providing care, information and support for chemotherapy-induced peripheral neuropathy

Date

22 Sep 2021

Session

Supportive care and symptom management (EONS-MASCC)

Presenters

Mary Anne Tanay

Citation

Annals of Oncology (2021) 32 (suppl_5): S1275-S1281. 10.1016/annonc/annonc697

Authors

M.A. Tanay1, G. Robert2, A.M. Rafferty2, R. Moss-Morris3, J. Armes4

Author affiliations

  • 1 Florence Nightingale Faculty Of Nursing, Midwifery And Palliative Care, King's College London, SE1 8WA - London/GB
  • 2 Florence Nightingale Faculty Of Nursing, Midwifery And Palliative Care, King's College London, London/GB
  • 3 Institute Of Psychiatry, Psychology And Neuroscience, King's College London, London/GB
  • 4 School Of Health Sciences, University of Surrey, Surrey/GB
More

Resources

Login to access the resources on OncologyPRO.

Abstract CN48

Background

Chemotherapy-induced peripheral neuropathy (CIPN), characterised by subjective sensory and motor symptoms felt on hands and feet, is one of the less known side-effects of chemotherapy. For many patients, their awareness of CIPN begins with information provided by clinicians during pre-chemotherapy consultations. However, there is limited understanding of how patients develop their understanding and perception of CIPN or of the experiences of clinicians providing CIPN information. This study explored patient’s and clinician’s experience of care provision, information and support for CIPN.

Methods

Data collection was conducted between July-November 2019 in a London hospital using multiple qualitative methods. Non-participant observations of pre-chemotherapy consultations between clinicians and people with breast or colorectal cancer (n= 9) were conducted. We also undertook semi-structured interviews with people who had breast or colorectal cancer (n=11) and clinicians (n=9). Data were analysed using inductive reflexive thematic analysis.

Results

Three major themes emerged. First, CIPN is a hidden chemotherapy side-effect not only because of its subjective nature but due to patient perspectives (e.g. fear of death, lack of familiarity with CIPN and evolving perception and understanding) and clinician perspectives (e.g. relative insignificance of CIPN, focus on acute symptoms, dependence on patient reporting and feelings of helplessness) that affect CIPN assessment and management. Second, the assessment and management of CIPN are disconnected. Finally, whilst openness was expected by both patients and clinicians when it comes to CIPN symptom reporting, information provision and management, this was not always forthcoming.

Conclusions

Our findings provide insights into patients’ and clinicians’ CIPN experiences. Issues such as patients’ lack of familiarity with CIPN, limited knowledge and understanding about CIPN among clinicians and fragmentation between CIPN assessment, management and support were highlighted. Our findings can inform future CIPN interventions that may better address patients’ support needs and enhance overall patient experience.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

King's College London.

Funding

National Institute for Health Research.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.